Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03471611
Other study ID # 17-005743
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 15, 2018
Est. completion date October 2, 2020

Study information

Verified date February 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?


Description:

This is an open label, phase I study to determine safety and efficacy of CD34+ cells in the treatment and management of CED and early atherosclerosis. Coronary endothelial function will be assessed in all patients by the administration of intracoronary acetylcholine. Patients with endothelial dysfunction who meet study inclusion criteria will receive granulocyte cell stimulating factor (G-CSF), followed by apheresis. The mobilized peripheral cell product will be processed for selection of CD34+ stem cells, and the purified CD34+ cells will be administered intracoronary during cardiac catheterization. The patients will undergo repeat endothelial function assessment 6 months post-procedure, as well as clinical assessments as described below either via in-person assessment by a nurse or physician, or via phone-call using a standardized questionnaire at 1, 3, and 6 month follow-up visits. At one month, the patient will undergo basic laboratory testing including troponin levels, complete blood count (CBC), electrolyte panel, liver function testing and ECG. At 3 months, the patients will receive a phone follow-up by the study coordinator who will assess the patient for any clinical deterioration or significant worsening in symptoms. At 6 months, the patients will return for a clinical visit, which will include physical examination, basic laboratory testing and follow-up acetylcholine study with angiography to assess for change in endothelial function. The first three patients will be sequentially enrolled, and subsequent enrollment will be held until one month follow-up. Provided there are no safety concerns at this time, enrollment will continue.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date October 2, 2020
Est. primary completion date October 2, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis of coronary endothelial dysfunction based on coronary angiogram and acetylcholine comprehensive coronary physiology study - Able to provide informed written consent and willing to participate in all required study follow-up assessments Exclusion Criteria: - Acute coronary syndrome or continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded. - Subjects in cardiogenic shock (systolic pressure < 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible. - Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine,prasugrel, etc). - Abnormal laboratory values (Hgb <11 mg/dL; glomerular filtration rate (GFR)<50; liver function tests (LFTs)>2x upper limit of normal). - Subjects receiving warfarin who have an international normalized ratio (INR) >2 at the end of the screening phase or with major bleeding requiring active transfusion support. - Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year. - Subjects with known severe immunodeficiency states (AIDS). - Significant coronary artery disease on coronary angiogram - Cirrhosis requiring active medical management. - Malignancy requiring active treatment (except basal cell skin cancer). - Subjects with documented active alcohol and /or other substance abuse. - Females of child bearing potential unless a pregnancy test is negative within 7 days of the bone marrow harvest. - Re-occlusion of the infarct related artery (IRA) prior to the infusion procedure. - Planned revascularization intervention during the next 6 months. (A second PCI can be performed if done prior to qualifying cardiovascular magnetic resonance imaging (CMR) at least 96 hours post primary PCI). - Participation in an ongoing investigational trial. - Active or suspected bacterial infection requiring systemic intravenous antibiotics. - Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator - Inmates

Study Design


Intervention

Drug:
Autologous CD34+ Cells
The dose will be 1x10^5 cells/kg, injected at the rate of 10 ml/min
Granulocyte Colony-Stimulating Factor (G-CSF)
5mg/kg twice daily

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects experiencing adverse events 12 months
Primary Number of subjects experiencing serious adverse events 12 months
Primary Number of subjects experiencing Major Adverse Cardiovascular Events (MACE) The most commonly reported major cardiovascular adverse events (MACE) include myocardial infarction, heart failure, percutaneous cardiac intervention, coronary artery bypass grafting, malignant dysrhythmia, cardiac shock, implantable cardiac defibrillator, malignant dysrhythmia and death. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03427996 - Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Not yet recruiting NCT04762472 - Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China Phase 4
Not yet recruiting NCT03174418 - Fluid-dynamics in Bifurcation PCI N/A
Not yet recruiting NCT03813017 - Comprehensive Assessment of Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis
Recruiting NCT05600088 - Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With NSTEMI or Unstable Angina N/A
Completed NCT03011775 - Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease Phase 4
Completed NCT00115583 - The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries N/A
Completed NCT03149042 - Validation of a Computed Tomography (CT) Based Fractional Flow Reserve (FFR) Software Using the 320 Detector Aquilion ONE CT Scanner.
Not yet recruiting NCT05540223 - Safety and Clinical Performance of the DREAMS 3G Resorbable Magnesium Scaffold System N/A
Completed NCT02389946 - Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions N/A
Completed NCT01234870 - Comprehensive Evaluation of Ischemic Heart Disease Using MRI Phase 2/Phase 3
Completed NCT00353795 - Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI) N/A
Enrolling by invitation NCT04810364 - HIV Infection And Evolvement of Atherosclerotic Plaque
Active, not recruiting NCT04175626 - Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Recruiting NCT00146887 - Comparison of Coronary CT Angiography to Invasive Coronary Angiography N/A
Completed NCT05492084 - Personalized Risk of Rapidly Progressive Atherosclerosis
Recruiting NCT04853511 - Comprehensive Assessment of Interconnection Between Brain Emotional Activity and Coronary Plaque Instability
Completed NCT03815032 - Assessing the Accuracy of the OptoWire DeuxTM in a Wire to Wire Comparison N/A
Active, not recruiting NCT03129503 - Optical Coherence Tomography in Acute Coronary Syndrome
Recruiting NCT06393894 - Latvian Early Atherosclerosis Registry

External Links